<?xml version="1.0" encoding="UTF-8"?>
<p>Additionally, the American company Cepheid developed a quick test which, as they declare, takes 45 min, while the Dutch pharmacists owning Qiagen developed a 1-h test. The US Food and Drug Administration has issued an emergency authorization of use for Cepheidâ€™s point-of-care COVID-19 diagnostics, Xpert Xpress SARS-CoV-2, according to a statement from the agency. The test was designed to provide detection of novel coronavirus within a short period of 45 min, using specimens from a nasopharyngeal swab, nasal wash/aspirate. Another POCT, the Xpert Xpress SARS-CoV-2 test cartridge is dedicated to detecting SARS-CoV-2 nucleic acid utilizing RT-qPCR and does not require the use of reagents. In the contrary, the GeneXpert System needs the test to be run in a CLIA-approved laboratory (Clinical Laboratory Improvement Amendments) or in a selection of patient care settings [
 <xref rid="B19-diagnostics-10-00434" ref-type="bibr">19</xref>].
</p>
